Polo box domain (PBD) from Polo-Like Kinase-1 (PLK-1) a cell cycle regulator is one of the important non-kinase targets implicated in various cancers. The crystal structure of PLK-1 PBD bound to phosphopeptide inhibitor is available and acylthiourea derivatives have been reported as potent PBD inhibitors. In this work, structure and ligand-based pharmacophore methods have been used to identify new PBD inhibitors. The binding of acylthiourea analogs and new inhibitors to PBD were assessed using molecular docking and molecular dynamics simulations to understand their binding interactions, investigate the complex stability and reveal the molecular basis for inhibition. This study provides the binding free energies and residue-wise contributions to decipher the essential interactions in the protein-inhibitor complementarity for complex formation and the design of new PBD inhibitors with better binding. Communicated by Ramaswamy H. Sarma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/07391102.2018.1515663 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fine-tuning probes for fluorescence polarization binding assays of bivalent ligands against polo-like kinase 1 using full-length protein.
Bioorg Med Chem
December 2024
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 1050 Boyles St., Frederick, MD 21702, USA.
Polo-like kinase 1 (Plk1) is an important cell cycle regulator that is a recognized target for development of anti-cancer therapeutics. Plk1 is composed of a catalytic kinase domain (KD), a flexible interdomain linker and a polo-box domain (PBD). Intramolecular protein-protein interactions (PPIs) between the PBD and KD result in "auto-inhibition" that is an essential component of proper Plk1 function.
View Article and Find Full Text PDFExploiting the chemical diversity space of phosphopeptide binding to nasopharyngeal carcinoma PLK1 PBD domain with unnatural amino acid building blocks by using QSAR-based genetic optimization.
SAR QSAR Environ Res
October 2024
Department of Otorhinolaryngology, Zhejiang Taizhou Hospital Affiliated to Wenzhou Medical University, Linhai, China.
Article Synopsis
- - The study focuses on human polo-like kinase 1 (PLK1) as a potential target for treating nasopharyngeal carcinoma (NPC), emphasizing its specific polo-box domain (PBD) that interacts with various substrates.
- - Researchers introduced a genetic optimization strategy to enhance the binding affinity of a 10-sized 6-mer phosphopeptide array by utilizing both natural (20) and unnatural (34) amino acids, leading to the design of three potent phosphopeptides with varying affinities.
- - Among the designed peptides, uPP20 demonstrated strong anti-tumor activity against NPC cells when combined with a cell-penetrating sequence, while the study also established a preferred 6-mer binding motif for PL
Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents.
Pharmaceuticals (Basel)
October 2024
Experimental Therapeutics Unit, Hospital Clínico San Carlos (HCSC), Instituto de Investigación Sanitaria San Carlos (IdISSC), 2546 Madrid, Spain.
ADCs have emerged as a promising class of therapeutics, combining the targeting specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. Although the majority of approved ADCs are still based on microtubule binder payloads, the recent success of topoisomerase I inhibitors has revitalized interest in the identification of novel agents overcoming present limitations in the field including narrow therapeutic window and chemoresistance. The success of DNA binders as payload for ADCs has been very limited, up to now, due, among other factors, to high hydrophobicity and planar chemical structures resulting in most cases in ADCs with a strong tendency to aggregate, poor plasma stability, and limited therapeutic index.
View Article and Find Full Text PDFPhase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.
Leuk Lymphoma
December 2024
Mayo Clinic, Rochester, MN, USA.
Article Synopsis
- - MEDI2228 is an antibody drug conjugate designed to target B-cell maturation antigen (BCMA) and was tested in a phase 1 trial for patients with relapsed/refractory multiple myeloma after prior treatments with standard medications.
- - The trial involved 107 patients, identifying a maximum tolerated dose of 0.14 mg/kg every three weeks, with common side effects including photophobia, rash, and thrombocytopenia; two patients experienced serious dose-limiting toxicities.
- - Although MEDI2228 showed promising efficacy with a 56.1% objective response rate in one treatment group, ocular toxicity issues led to the decision not to pursue further development of the drug.
Key Clinical Message: This case emphasizes the need for early recognition and accurate diagnosis of achalasia in young adults to avoid exacerbation of the condition and misdiagnosis as GERD. Patient outcomes and quality of life are greatly enhanced by suitable diagnostic techniques, appropriate therapy, interdisciplinary care, and comprehensive patient education along with frequent follow-ups.
Abstract: Achalasia results from the degeneration of inhibitory ganglion cells within the esophageal myenteric plexus and the lower esophageal sphincter (LES), leading to a loss of inhibitory neurons and resulting in the absence of peristalsis with failure of LES relaxation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!